Bitcoin price today: little changed near $119k ahead of Fed meet, tariff deadline
Investing.com -- Fresenius, the global healthcare group, confirmed its financial guidance for FY25. The company’s shares saw a slight increase of 0.7% in early trading following this announcement.
The group’s revenue is expected to see an organic growth of 4-6%. The consensus estimate was 5.5%. The company’s adjusted EBIT is projected to grow 3-7% on a constant exchange rate (CER) basis, however, no specific EBIT margin target was provided. The consensus estimate for the EBIT margin was 11.5%, while Jefferies expected it to be 11.4%.
Fresenius Kabi, the company’s pharmaceutical and medical devices division, is expected to see mid to high single-digit organic growth, compared to the consensus estimate for this growth was 6.6%%. The adjusted EBIT margin for Kabi is projected to be 16-16.5%, with the consensus at 16.3%. The structural EBIT band for this division is 16-18%.
The company’s Helios division is projected to see mid-single-digit organic growth. The consensus estimate for this growth was 5.0%. The adjusted EBIT margin for Helios is expected to be around 10%, with the consensus estimating it to be 9.9% and Jefferies estimating it to be 9.8%.
The company’s leverage is projected to be 2.5-3.0x. The dividend policy of the company is to distribute 30-40% of the core net income. The company’s interest expense is expected to be €370m to €390m, which is a reduction from the previous estimate of €400m to €420m.
In the first quarter of FY25, the group’s revenue was €5,631m, slightly above the consensus estimate of €5,613m. This represented an organic growth of around 7%, which was higher than the consensus estimate of 6.1%. The adjusted EBIT for the quarter saw a CER growth of 4% with an 11.6% margin, which was higher than the consensus estimate of 11.3%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.